Report cover image

Cell and Gene Therapy Market and Deals Analysis, 2023: Financings, Partnering, Mergers and Acquisitions, Tech Transfers, IPOs, and Other Deals

Publisher Kalorama Information
Published May 01, 2023
Length 261 Pages
SKU # KLI18014722

Description

Cell and Gene Therapy Market and Deals Analysis, 2023: Financings, Partnering, Mergers and Acquisitions, Tech Transfers, IPOs, and Other Deals


This report, Kalorama's Cell and Gene Deals and Market Analysis, tracks the dealmaking and market opportunity for cell and gene therapy companies. A lot of attention is being given to the areas related to cell and gene therapy (CGT) recently. Kalorama's latest report finds that the volume of deals between companies and other funding entities involving CGT is up, and companies have continued to receive large amounts of investment despite a decline from 2021 levels of investment.

Kalorama's CGT deals amounted to a staggering $40 billion in 2022.

While the concepts of gene therapy and cell therapy have been investigated for decades, there were major challenges in the early years. Through incremental progress, and the gradual introduction of enabling tools such as CRISPR and next-generation sequencing (NGS), cell and gene therapy has emerged into a highly active area. There are now many approved therapies with proven track records.

As the new tools have lowered the barriers to entry for the industry, over 1,500 companies have been created or have become involved.

The following is just some of the information in this report:
  • Most Active Deal-Making Companies
  • Deals per Month, April 2021-March 2023
  • Deals by Type - Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation
  • Venture Capital and Private Funding Deals by Month, January 2021-March 2023 (Total count)
  • Regional Venture Capital/Private Funding Shares [North America, Europe, APAC, Rest of World] (%)
  • Total Number of Mergers and Acquisitions, By Month
  • Average Merger/Acquisition Amount, By Quarter [Q1 2021-Q1 2023] ($M)
  • List of M&As [Company 1, Company 2, Details, Amount, w/Milestones, Date]
  • Most Frequent Types of Deals, by Quarter, by Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; and Manufacturing, Supply Chain] (Total number)
  • Most Active Companies in Acquisition/Merger/ Strategic Investment
  • Most Active Companies in Overall Deals, Collaborations
  • Estimated Market Forecasts for Cell and Gene Therapies by Type (Gene Therapy, Cell Therapy)
  • Estimated Market Forecasts by Region (North America, EU, APAC, Other)
  • Estimated Market Forecasts for CGT by Disease Category (Oncology, Other)
No report published by a major market research publisher has tackled the Cell and Gene Therapy dealmaking space as it exists in 2023 in a more comprehensive fashion. As Cell and Gene Therapy is a highly competitive marketplace, hundreds of companies are referenced in this report.

Table of Contents

261 Pages
    • Introduction
    • $40.2 Billion in Funding During 2022
    • Quarterly Funding Amounts
    • Quarterly Funding Category Shares, Q1 2021 Through Q1 2023
    • Synopsis of Most Active Deal-Making Companies
    • VC/Private Funding in Flux
    • Strategic Investments in Cell and Gene Therapy
    • Most Active Companies
    • North America Sees the Majority of Proceeds from IPOs, FPOs, SPACs
    • Growing Numbers of M&A, Despite Lower Average Value
    • Most Active Companies
    • CGT Market Sees a Broad Variety of Collaborations
    • Most Active Companies
    • Stable Levels of Licensing in the Cell and Gene Therapy Market
    • Most Active Companies
    • Major Growth in Manufacturing and Supply Chain Management Activity in CGT
    • Most Active Companies
    • CGT Market Focusing Less on Public Outreach, Patient/ Consumer/ Trainee Education, and Philanthropy
    • A Look at CGT Distribution and Co-Marketing Deals
    • Most Active Companies
    • A Look at Other Types of Deals Impacting Cell and Gene Therapy
    • Expansion, New Facilities and Related Announcements
    • Market Outlook, 2022-2032
    • Regional Market
    • Products on the Market
    • Top Companies in Cell and Gene Therapy

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us